NCT04468282View on ClinicalTrials.gov

Bioequivalence Study of Vigabatrin ORPHELIA Pharma 500mg Soluble Tablets and SabrilTM 500mg Granules for Oral Administration

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

April 4, 2017

Primary Completion Date

August 8, 2017

Study Completion Date

August 8, 2017

Conditions

Therapeutic Equivalency

Interventions

DRUG

VGB-ST

Single oral administration of 500 mg VGB-ST

Trial Locations (1)

38610

Eurofins Optimed, Gières

Sponsors

Lead Sponsor

Orphelia Pharma

All Listed Sponsors

lead

Orphelia Pharma

INDUSTRY

NCT04468282 - Bioequivalence Study of Vigabatrin ORPHELIA Pharma 500mg Soluble Tablets and SabrilTM 500mg Granules for Oral Administration | Biotech Hunter | Biotech Hunter